Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Caspian Therapeutics | Sep 2026Led | $50 MOther Equity | |
Superluminal Medicines | Sep 2026Led | $60 MSeries B | |
Expedition Therapeutics | Aug 2026Participated | $115 MSeries B | |
Contraline | Jun 2026Led | $93 MSeries B | |
Ambrosia Biosciences | Mar 2026Participated | $100 MSeries B | |
Crossbow Therapeutics | Mar 2026Participated | $77 MSeries B | |
Angitia Biopharmaceuticals | Feb 2026Participated | $130 MSeries D | |
Third Arc Bio | Feb 2026Participated | $52 MSeries A | |
Diagonal Therapeutics | Jan 2026Participated | $125 MSeries B | |
Expedition Therapeutics | Oct 2025Participated | $165 MSeries A | |
Antares Therapeutics | Jun 2025Led | $177 MSeries A | |
Merida Biosciences | Apr 2025Led | $121 MSeries A | |
Caspian Therapeutics | Sep 2026Led | $50 MOther Equity | |
Superluminal Medicines | Sep 2026Led | $60 MSeries B | |
Expedition Therapeutics | Aug 2026Participated | $115 MSeries B | |
Contraline | Jun 2026Led | $93 MSeries B | |
Ambrosia Biosciences | Mar 2026Participated | $100 MSeries B | |
Crossbow Therapeutics | Mar 2026Participated | $77 MSeries B | |
Angitia Biopharmaceuticals | Feb 2026Participated | $130 MSeries D | |
Third Arc Bio | Feb 2026Participated | $52 MSeries A | |
Diagonal Therapeutics | Jan 2026Participated | $125 MSeries B | |
Expedition Therapeutics | Oct 2025Participated | $165 MSeries A | |
Antares Therapeutics | Jun 2025Led | $177 MSeries A | |
Merida Biosciences | Apr 2025Led | $121 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 6 | 16 |
| Series B | 8 | 33 |
| Series C+ | 1 | 21 |
| Other Equity | 4 | 9 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '14 | 1 |
| Feb '14 | 0 |
| Mar '14 | 0 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 0 |
| Oct '14 | 0 |
| Nov '14 | 2 |
| Dec '14 | 0 |
| Jan '15 | 0 |
| Feb '15 | 0 |
| Mar '15 | 1 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 1 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 1 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 1 |
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 3 |
| Apr '18 | 0 |
| May '18 | 1 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 2 |
| Jan '19 | 0 |
| Feb '19 | 1 |
| Mar '19 | 1 |
| Apr '19 | 2 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 1 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 1 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 2 |
| Jul '20 | 3 |
| Aug '20 | 0 |
| Sep '20 | 1 |
| Oct '20 | 3 |
| Nov '20 | 1 |
| Dec '20 | 1 |
| Jan '21 | 3 |
| Feb '21 | 3 |
| Mar '21 | 1 |
| Apr '21 | 6 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 1 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 4 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 3 |
| Feb '22 | 3 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 2 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 2 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 1 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 2 |
| Aug '23 | 1 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 2 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 2 |
| Jun '24 | 0 |
| Jul '24 | 2 |
| Aug '24 | 1 |
| Sep '24 | 1 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 2 |
| Mar '26 | 2 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 1 |
| Jul '26 | 0 |
| Aug '26 | 1 |
| Sep '26 | 2 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 99 |
| Consumer & Lifestyle | 4 |
| Space & Frontier Tech | 2 |
| Manufacturing | 1 |
| AI & Machine Learning | 1 |
| Professional Services | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 0 |
| $10M-$25M | 5 |
| $25M-$50M | 13 |
| $50M-$100M | 34 |
| $100M-$250M | 44 |
| $250M-$500M | 2 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 90 |
| Europe | 4 |
| Canada | 3 |
| V5t 1m4 | 1 |
| China | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| RA Capital Management | 34 |
| Logos Capital | 26 |
| Janus Henderson Investors | 25 |
| Samsara BioCapital | 19 |
| Cormorant Asset Management | 18 |
| Boxer Capital | 16 |
| Perceptive Advisors | 16 |
| Casdin Capital | 15 |
| Surveyor Capital | 15 |
| OrbiMed | 13 |
| Alexandria Venture Investments | 12 |
| Atlas Venture | 12 |
| Invus | 11 |
| Nextech Invest | 11 |
| Pfizer Ventures | 11 |
| EcoR1 Capital | 9 |
| Foresite Capital | 9 |
| Google Ventures | 9 |
| Venrock | 9 |
| Cowen Healthcare Investments | 8 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 20 | 20% |
| Participating | 79 | 80% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 8 | 40% |
| Co-led | 12 | 60% |
Team
Managing Director
Chief Financial Officer, Chief Compliance Officer
President, CEO/Founder
Portfolio Manager
Managing Director
Business & Operations
Principal
Managing Director
